Cognition Therapeutics (CGTX) Insider Trading & Ownership $0.46 -0.05 (-9.78%) (As of 11/15/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Cognition Therapeutics (NASDAQ:CGTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage20.75%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$9,975.00Number OfInsiders Selling(Last 12 Months)0 Get CGTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Cognition Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CGTX Insider Buying and Selling by Quarter Ad Porter & CompanyUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Cognition Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/14/2024Lisa RicciardiCEOBuy5,700$1.75$9,975.00 (Data available from 1/1/2013 forward) CGTX Insider Trading Activity - Frequently Asked Questions Who is on Cognition Therapeutics's Insider Roster? The list of insiders at Cognition Therapeutics includes Ellen B Richstone, Lisa Ricciardi, and Peggy Wallace. Learn more on insiders at CGTX. What percentage of Cognition Therapeutics stock is owned by insiders? 20.75% of Cognition Therapeutics stock is owned by insiders. Learn more on CGTX's insider holdings. Which Cognition Therapeutics insiders have been buying company stock? The following insiders have purchased CGTX shares in the last 24 months: Ellen B Richstone ($26,500.00), and Lisa Ricciardi ($9,975.00). How much insider buying is happening at Cognition Therapeutics? Insiders have purchased a total of 15,700 CGTX shares in the last 24 months for a total of $36,475.00 bought. Cognition Therapeutics Key ExecutivesMs. Lisa Ricciardi (Age 64)CEO, President & Director Compensation: $854.15kMr. John Brendan Doyle (Age 47)Chief Financial Officer Compensation: $414.88kDr. Anthony O. Caggiano M.D. (Age 54)Ph.D., Chief Medical Officer and Head of R&D Compensation: $616.27kDr. Steven A. Weissman Ph.D.VP & Head of CMC More Insider Trading Tools from MarketBeat Related Companies Bolt Biotherapeutics Insider Buying Avalo Therapeutics Insider Buying MiNK Therapeutics Insider Buying Elevation Oncology Insider Buying Aerovate Therapeutics Insider Buying CytomX Therapeutics Insider Buying IO Biotech Insider Buying ESSA Pharma Insider Buying DBV Technologies Insider Buying Prelude Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (NASDAQ:CGTX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
